The place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease: French experience
JAKis offer another therapeutic option for patients with SJIA-LD. However, the risk of MAS argues for caution about stopping anti-IL-1s when introducing JAKis. Tolerance needs careful monitoring in larger studies..
Authors
- Étienne Merlin (ORCID: https://orcid.org/0000-0001-6527-7893)
- Isabelle Melki (ORCID: https://orcid.org/0000-0002-8057-333X)
- Alexandre Bélot (ORCID: https://orcid.org/0000-0003-4902-5332)
- Véronique Hentgen (ORCID: https://orcid.org/0000-0003-1788-1898)
- G Cote
- Pierre Quartier (ORCID: https://orcid.org/0000-0002-1769-549X)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Hôpital Necker-Enfants Malades (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Robert-Debré (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre Hospitalier de Versailles (FR)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1093/rheumatology/keae589
- Citations
- 1
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45